Cosette Pharmaceuticals Acquires Assertio Holdings Portfolio for $48.9 Million

Cosette Pharmaceuticals has successfully closed a definitive agreement to acquire the U.S. sales and distribution rights for seven branded products from Assertio Holdings, Inc. for $48.9 million. The acquisition notably includes SYMPAZAN®, an FDA-approved treatment for Lennox-Gastaut Syndrome with patent protection extending until 2040. This strategic move is designed to advance Cosette's disciplined growth strategy and significantly expand its branded pharmaceutical footprint in the United States. For Assertio, the divestiture provides a strategic opportunity to bolster its liquidity position as it prepares for its own recently announced acquisition by Garda Therapeutics. The integration of these revenue-generating assets is expected to provide immediate and long-term value to Cosette's specialty portfolio. This transaction highlights the ongoing consolidation and strategic refocusing trends within the pharmaceutical industry.